Close
Nordic 9Nordic 9

Forty51 Ventures (investor - None)

Switzerland forty51ventures.com
See something wrong or missing? Let us know
Offices:Basel

Forty51 Ventures is a Swiss investment fund launched by Sascha Oliver Bucher in 2022

Average round investment:41.75M USD
Average number per year:1.0
Distribution: 2025 (1)2024 (1)
Portfolio companies: Switzerland Mosanna TherapeuticsSwitzerland Allegria Therapeutics
Mostly invests in: Switzerland Switzerland (2) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Forty51 Ventures

Name Criteria
United States Acorn Bioventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States KB Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Recipharm Venture Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France BOLD - Business Opportunities for L'Oréal Development
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Fresenius Medical Care Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland GF Group
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland EGS Beteiligungen AG
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Pierre Fabre Invest
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Piper Private Equity
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Switzerland Bernina BioInvest
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Top